References

1. Invernizzi RI, Martinelli B, Pinotti G. Association of GIST, breast cancer and schwannoma in a 60-year-old woman affected by type-1 von Recklinghausen's neurofibromatosis. Tumori. 2008; 94(1): 126-128. PubMed | Google Scholar


2. Takeuchi H, Hiroshige S, Hashimoto K, KAsumoto T, Yushikawa Y, Muto Y. Synchronous Double Tumor of Breast Cancer and Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1: Report of a Case. ANTICANCER RESEARCH. 2011; 31(12): 4481-4484. PubMed | Google Scholar


3. Agaimy A, Wunsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin diagn pathology. 2006; 23(2):120-9. PubMed | Google Scholar


4. Milandri C, Passardi A, Dall'agata M, Cecconetto L. Gastrointestinal stromal tumors and breast cancer: Any correlation? Report of two clinical cases. Journal of Clinical Oncology, 2005; 23 (June 1 Supplement): 9049. Google Scholar


5. Ruben BP,Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, and al. KIT activating is a abiquitous feature of gastro intestinal stromal tumor. Cancer Research. 2001; 6 (22): 8118-21. PubMed | Google Scholar


6. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamagushi J, HAshizume Y, and al. Gastrointestinal stromal tumours of neurofibromatosis type 1 (Von Recklinghausen's disease). Am J Surg Pathol. 2005; 29(6): 755- 763. PubMed | Google Scholar


7. Schiavon G, Maki R, Fornier M. GIST and breast cancer: 3 cases reports and a review of literature. Current Cancer therapy reviews. 2009; 5 (2): 100-104. PubMed | Google Scholar


8. Haouala A, Widmer N, Michel A, Montemurro M, Buclin T, Decosterd LA. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood journal hematology ,2011; 117(8): 75-87. Google Scholar